| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c1ed9172be30413aa370d8589890799
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62924da566ff64c0088b4cdc3af46923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a583ac8ac8f8c952847026833ecda0ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91e2cb26955bbd751109d3c35b48a395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13e4c13fe64996895413453879610c3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 |
| filingDate |
2008-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78a4c3281b02f30bd386fdff6d8642d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5845829d1f511afe20e8ad3795dc899
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac567c055fb2dc185b3f777ee113981e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39e7ec0b1185a9fdff844e94c7445173 |
| publicationDate |
2008-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008109376-B1 |
| titleOfInvention |
Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof |
| abstract |
The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing BCR-ABL gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BCR-ABL mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a BCR-ABL gene in a cell or in a subject to treat a BCR-ABL-related disease. |
| priorityDate |
2007-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |